Get the latest news, insights, and market updates on PGEN (Precigen, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2025 financial results and provide business updates on Thursday, November 13, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. Nov 6, 2025 - $PGEN
Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS
Precigen Inc. (NASDAQ:PGEN) is one of the hot stocks to buy with huge upside potential. On October 13, Precigen announced long-term follow-up data for PAPZIMEOS (zopapogene imadenovec-drba), which is an immunotherapy for the treatment of adults with recurrent respiratory papillomatosis/RRP. PAPZIMEOS received full approval from the US FDA in August this year, becoming the first […] Oct 26, 2025 - $PGEN
A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis
Precigen (PGEN) has drawn investor attention following the full FDA approval of its PAPZIMEOS therapy for adults with recurrent respiratory papillomatosis. The approval is backed by strong, long-term clinical data showing lasting complete responses and fewer surgeries. See our latest analysis for Precigen. Following the therapy’s landmark approval, Precigen’s 1-year total shareholder return has soared an impressive 281%, with shares trading at $3.49. This momentum has only intensified since... Oct 17, 2025 - $PGEN
3 High Growth Stocks With Strong Insider Ownership
As the U.S. stock market experiences a rebound with major indices like the Nasdaq and S&P 500 showing gains following softened trade tensions with China, investors are keenly observing sectors that promise robust growth potential. In such an environment, stocks of growth companies with high insider ownership can be particularly appealing, as this combination often signifies confidence in the company's future prospects and alignment between management and shareholder interests. Oct 13, 2025 - $PGEN
Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Precigen, Inc. is one of them. Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company developing precision genetic medicines for oncology, infectious diseases, and rare conditions. Its platforms include OmniCAR for adaptable CAR T-cell therapies and […] Sep 23, 2025 - $PGEN
Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization
Precigen, Inc. (NASDAQ:PGEN) is one of the best healthcare penny stocks to buy now. On September 2, the company entered into a credit facility agreement with investment funds managed by Pharmakon Advisors. The company will have access to a credit line of up to $125 million, divided into two tranches of $100 million and $25 […] Sep 20, 2025 - $PGEN
Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS
Precigen, Inc. (NASDAQ:PGEN) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 3, Precigen, Inc. (NASDAQ:PGEN) announced that it signed a credit facility agreement with total funds of up to $125 million. Precigen entered into a credit facility agreement with investment funds managed by Pharmakon Advisors. The […] Sep 15, 2025 - $PGEN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple